drugset / Trial / NCT02747342
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2016-09
- Primary completion
- 2019-06-28
- Completion
- 2020-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | — | — |
| Subject | Rezvilutamide | Small molecule | — | Oral |